Advanced Search
Contact | Corporate | Help

Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer

Sponsors:
  • St John Health Oncology Research Consortium
  • Genentech
  • Eli Lilly and Company
Phases:
  • Phase II
IndicationsAcronym:
  • Non-Small Cell Lung Cancer
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: bevacizumab
  • Drug: carboplatin
  • Drug: gemcitabine
Enrollment:
45

Additional information about NCT00150657.


SourceSolution © 2008-2012